Effect of Novel Biotherapeutic Elevating Angiopoietin 1 on Progression of Diabetic Nephropathy in Diabetic/Obese Mice

Authors :: Peng, Sun
Christina S, Bartlett
Chao, Zheng
Tammy, Bigwarfe
Joshuaine M, Grant
Margit, MacDougall
Valentina, Berger
Steven, Kerr
Hu Sheng, Qian
Mark, McHugh
Hongxing, Chen
Xiaomei, Zhang
Miranda L, Carpenter
Heather N, Robinson
John, Miglietta
Thorsten, Lamla
Ryan M, Fryer
Source :: Journal of Pharmacology and Experimental Therapeutics. 382:266-276
Publication Year :: 2022
Publisher :: American Society for Pharmacology & Experimental Therapeutics (ASPET), 2022.
Abstract: Diabetic nephropathy is a leading cause of end-stage renal disease, characterized by endothelial dysfunction and a compromised glomerular permeability barrier. Dysregulation of the angiopoietin 1 (ANGPT1)/angiopoietin 2 (ANGPT2) signaling axis is implicated in disease progression. We recently described the discovery of an IgG

Subjects :: Angiopoietin-2
Pharmacology
Mice
Epidermal Growth Factor
Angiopoietin-1
Diabetes Mellitus
Albuminuria
Animals
Mice, Obese
Molecular Medicine
Diabetic Nephropathies
Protein-Tyrosine Kinases

Tools